… , the failure to develop successful vaccines against the most common … vaccines against
genital human papillomaviruses (HPVs). In recently concluded clinical trials, these vaccines were …

… human papillomavirus (HPV) is necessary for the development and maintenance of cervical
cancer. Thus, effective vaccination … The FDA recently approved the HPV vaccine Gardasil for …

The papers are reviewed by external experts and WHO staff, and reviewed and endorsed by
the WHO Strategic Advisory Group of Experts (SAGE) on immunization (http://www. who. int/…

… human papillomavirus (HPV) vaccine was first introduced for females in the United States in
2006, vaccination policy has evolved as additional HPV vaccines … Vaccination coverage is …

We present a transmission dynamic model that can assess the epidemiologic consequences
and cost-effectiveness of alternative strategies of administering a prophylactic quadrivalent (…

… vaccines are safe and highly effective against the most common human papillomavirus (HPV) …
Implementation of HPV vaccination is lagging where it is most needed: in the poorest and …

Human papilloma virus (HPV) infections, which are common, produce epithelial lesions of the
nongenital and genital skin and mucous membranes. Although most infections are benign …

… key element in the choice of human papillomavirus (HPV) vaccine to use in vaccination
programmes. We compared the cross-protective efficacy of the bivalent vaccine (HPV 16 and 18; …

… human papillomavirus vaccination in a screened population. We considered in a separate
scenario estimates of vaccine … , we assumed that a human papillomavirus vaccine reduces the …

… that use virus-like particles as a vaccine antigen. This review discusses the current status
of HPVs vaccines on the global market, clinical trials, and the future of HPVs vaccine …